Experience with the HIV protease inhibitor fosamprenavir in first-line antiretroviral therapy regimens in the Chelyabinsk Region


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the efficiency and economic advisability of first-line antiretroviral therapy (ARVT) regimens including fosamprenavir and ritonavir (FPV/r) in a dose of1400/100 mg once daily in previously untreated patients. Subjects and methods. The data on 43 adult HIV-infected patients were retrospectively analyzed. The proportion of patients with undetectable viral load and the levels of CD4 lymphocytes were estimated at 12, 24, 48, and 72 weeks; direct costs of test ARVT regimens were calculated. Results. The vast majority of patients achieved the undetectable level of viral load (HIV RNA < 150 copies/ml) just at 24 weeks of ARVT with FPV/r regardless of the prescribed nucleoside base. The maximum increment (+ 1158%) of CD4 lymphocyte count was noted in a group of patients receiving FPV/r in combination with abacavir/lamivudine (ABC/3TC). The ABC/3TC + FPV/r regimen proved to be more unprofitable; however, due to some benefits (once daily use, minimum pills load, favorable tolerability profile) it was optimal for patients in first-line ARVT. Conclusion. Once daily FPV/r in the first-line ARVT regimens showed its high efficiency irrespective of the used nucleoside base; the best immunological efficiency was demonstrated when FPV/r was taken in combination with ABC/3TC.

Full Text

Restricted Access

About the authors

M. G Moskvicheva

South-Ural State Medical University, Ministry of Health of Russia

Email: fpdpo@mail.ru

M. V Radzikhovskaya

Chelyabinsk Regional Center for the Prevention and Control of AIDS and Infectious Diseases

Email: rita-rad@mail.ru

References

  1. Mallolas J., Blanco J.L., Pich J., Arnaizb J., Penac J., Dalmaud D. et al. A randomized trial comparing the efficacy and toler-ability of two HAART strategies at two years in antiretroviral naive patients. Rev. Clin. Esp. 2007; 207(9): 427-432.
  2. MacArthur R.D., Novak R.M., Peng G., Chen L., Xiang Y., Hullsiek K. et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368(9553): 2125-2135.
  3. Bartlett J.A., Fath M.J., Demasi R., Hermes A., Quinn J., Mondou E. et al. An updated systematic overview of triple combination therapy in antiretroviralnaive HIV-infected adults. AIDS 2006; 20(16): 2051-2064.
  4. Riddler S.A., Haubrich R., DiRienzo A.G., Peeples L., Powderly W., Klingman K. et al. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 2008; 358: 2095-2106.
  5. Pulido F., Estrada V., Baril J.G., Logue K., Schewe K., Plettenberg A. et al. Long-term efficacy and safety of Fosamprenavir plus Ritonavir versus Lopinavir/Ritonavir in combination with Abacavir/Lamivudine over 144 weeks. HIV Clin. Trials 2009; 10(2): 76-87.
  6. Walmsley S., Avihingsanon A., Slim J., Ward D., Ruxrungtham K., Brunetta J. et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J. Acquir. Immune Defic. Syndr. 2009; 50(4): 367-374.
  7. Molina J., Andrade-Villanueva J., Echevarria J., Chetchotisakd P., Corral J., David N. et al. Once-daily Atazanavir/Ritonavir compared with twice-daily Lopinavir/Ritonavir, each in combination with Tenofovir and Emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J. Acquir. Immune Defic. Syndr. 2010; 53(3): 323-332.
  8. Ortiz R., Dejesus E., Khanlou H., Voronin E., van Lunzen J., Andrade-Villanueva J. et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
  9. Calza L., Manfredi R., Pocaterra D., Chiodo F. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopina-virritonavir-based antiretroviral treatment in 82 therapy-nave patients with HIV-1 infection. International Journal of STD & AIDS 2008; 19: 541-544.
  10. Hicks C., DeJesus E., Sloan L., Sension M.G., Wohl D.A., Liao Q. et al. Comparison of once-daily Fosamprenavir boosted with either 100 or 200 mg of Ritonavir, in combination with Abacavir/Lamivudine: 96-week results from COL100758. AIDS Res. Hum. Retroviruses 2009; 25(4): 395-403.
  11. Cohen C., DeJesus E., LaMarca A., Young B., Yau L., Patel L. et al. Similar virologic and immunologic efficacy with fosam-prenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. HIV Clin. Trials. 2010; 11(5): 239-247.
  12. Smith K., Weinberg W., DeJesus E., Fischl M., Liao Q., Ross L. et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res. Ther. 2008. doi: 10.1186/1742-6405-5-5
  13. EACS Guidelines. October 2013. http://www.europeanaid-sclinicalsocity.org
  14. DHHS Guidelines. February 2013. http://www.aidsinfo.nih. gov/guidelines
  15. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2013; 6, приложение.
  16. Мазус А.И., Каминский Г.Д., Зимина В.Н., Бессараб Т.П., Пронин А.Ю., Цыганова Е.В. и др. Национальные клинические рекомендации по диагностике и лечению ВИЧ-инфекции у взрослых. М., 2013. 68 с.
  17. Лисицын Ю.П. Общественное здоровье и здравоохранение: учебник. Раздел 6. Теоретические и методологические основы статистики. 2-е изд. М.: ГЭОТАР-Медиа, 2010. 512 с.
  18. DeJesus E., Herrera G., Teofilo E., Gerstoft J., Buendia C.B., Brand J.D. et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 2004; 39(7): 1038-1046.
  19. Sullivan P., Hanson D., Chu S., Jones J.L., Ward J.W. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301-308.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies